<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38863076</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jun</Month><Day>12</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>Colchicine to reduce coronavirus disease-19-related inflammation and cardiovascular complications in high-risk patients post-acute infection with SARS-COV-2-a study protocol for a randomized controlled trial.</ArticleTitle><Pagination><StartPage>378</StartPage><MedlinePgn>378</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">378</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-024-08205-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is no known effective pharmacological therapy for long COVID, which is characterized by wide-ranging, multisystemic, fluctuating, or relapsing symptoms in a large proportion of survivors of acute COVID. This randomized controlled trial aims to assess the safety and efficacy of an anti-inflammatory agent colchicine, to reduce symptoms among those at high risk of developing long COVID.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This multi-centre, parallel arm, 1:1 individual randomized, placebo-controlled, double-blind superiority trial will enrol 350 individuals with persistent post-COVID symptoms. Participants will be randomized to either colchicine 0.5&#xa0;mg once daily (&lt;&#x2009;70&#xa0;kg) or twice daily (&#x2265;&#x2009;70&#xa0;kg) or matched placebo for 26&#xa0;weeks and will be followed up until 52&#xa0;weeks after randomization. The primary trial objective is to demonstrate the superiority of colchicine over a placebo in improving distance walked in 6&#xa0;min at 52&#xa0;weeks from baseline. The secondary objectives are to assess the efficacy of colchicine compared to placebo with respect to lung function, inflammatory markers, constitutional symptoms, and mental health state. In a sub-sample of 100 participants, cardiac biomarkers of myocardial injury and myocardial oedema using MRI will be compared.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Persistent inflammatory response following SARS-CoV-19 is one of the postulated pathophysiological mechanisms of long COVID. Colchicine, a low-cost anti-inflammatory agent, acts via multiple inflammatory pathways and has an established safety profile. This trial will generate evidence for an important health priority that can rapidly translate into practice.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">This clinical trial has been registered prospectively on www.</AbstractText><AbstractText Label="CLINICALTRIALS" NlmCategory="RESULTS">gov with registration CTRI/2021/11/038234 dated November 24, 2021.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thankachen</LastName><ForeName>Shani S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>The George Institute for Global Health India, UNSW, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devasenapathy</LastName><ForeName>Niveditha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>The George Institute for Global Health India, UNSW, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bassi</LastName><ForeName>Abhinav</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The George Institute for Global Health India, UNSW, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghosh</LastName><ForeName>Arpita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The George Institute for Global Health India, UNSW, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arfin</LastName><ForeName>Sumaiya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The George Institute for Global Health India, UNSW, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gummidi</LastName><ForeName>Balaji</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The George Institute for Global Health India, UNSW, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basheer</LastName><ForeName>Aneesh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Dr. Moopen's Medical College, Wayanad, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bangi</LastName><ForeName>Ashfak</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Jivenrekha Multispeciality Hospital, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sahu</LastName><ForeName>Dibakar</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Sleep and Critical Care, All India Institute of Medical Science, Raipur, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhalla</LastName><ForeName>Ashish</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Postgraduate Institute of Medical Education &amp; Research, Chandigarh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blesson</LastName><ForeName>Merlin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Amrita Institute of Medical Science, Kochi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Manish</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Medicine, Maharaja Agrasen Hospital, Jaipur, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jha</LastName><ForeName>Vivekanand</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-8015-9470</Identifier><AffiliationInfo><Affiliation>The George Institute for Global Health India, UNSW, New Delhi, India. v.jha@imperial.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, Imperial College London, London, UK. v.jha@imperial.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India. v.jha@imperial.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ECD/CSTPU/Adhoc/COVID-19/13/2021-22</GrantID><Agency>Indian Council of Medical Research</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>SML2Y3J35T</RegistryNumber><NameOfSubstance UI="D003078">Colchicine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003078" MajorTopicYN="Y">Colchicine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Colchicine</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Lung function</Keyword><Keyword MajorTopicYN="N">Randomized controlled trial</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>12</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>11</Day><Hour>23</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38863076</ArticleId><ArticleId IdType="pmc">PMC11167886</ArticleId><ArticleId IdType="doi">10.1186/s13063-024-08205-7</ArticleId><ArticleId IdType="pii">10.1186/s13063-024-08205-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO. Weekly epidemiological update on COVID-19 2023 https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---22-june-2023. Accessed 22 Jun 2023</Citation></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. A clinical case definition of post COVID-19 condition by a Delphi consensus. World Health organization 2021 https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1. Accessed 6 Oct 2021</Citation></Reference><Reference><Citation>Tanayott Thaweethai P, Sarah E, Jolley M, ElizabethW. MS, Karlson M, Emily B. MS, Levitan S, Bruce Levy M, Grace A, McComsey M, et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA. 2023;329(22):1934&#x2013;1946. doi: 10.1001/jama.2023.8823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.8823</ArticleId><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Group P-CC Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med. 2022;10(8):761&#x2013;75. doi: 10.1016/S2213-2600(22)00127-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00127-8</ArticleId><ArticleId IdType="pmc">PMC9034855</ArticleId><ArticleId IdType="pubmed">35472304</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583&#x2013;590. doi: 10.1038/s41591-022-01689-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01689-3</ArticleId><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousif E, Premraj S. A review of long COVID with a special focus on its cardiovascular manifestations. Cureus. 2022;14(11):e31933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9793803</ArticleId><ArticleId IdType="pubmed">36582565</ArticleId></ArticleIdList></Reference><Reference><Citation>Koc HC, Xiao J, Liu W, Li Y, Chen G. Long COVID and its management. Int J Biol Sci. 2022;18(12):4768&#x2013;4780. doi: 10.7150/ijbs.75056.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.75056</ArticleId><ArticleId IdType="pmc">PMC9305273</ArticleId><ArticleId IdType="pubmed">35874958</ArticleId></ArticleIdList></Reference><Reference><Citation>Yelin D, Moschopoulos CD, Margalit I, Gkrania-Klotsas E, Landi F, Stahl JP, et al. ESCMID rapid guidelines for assessment and management of long COVID. Clin Microbiol Infect. 2022;28(7):955&#x2013;972. doi: 10.1016/j.cmi.2022.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.02.018</ArticleId><ArticleId IdType="pmc">PMC8849856</ArticleId><ArticleId IdType="pubmed">35182760</ArticleId></ArticleIdList></Reference><Reference><Citation>Callard F, Perego E. How and why patients made long COVID. Soc Sci Med. 2021;268:113426. doi: 10.1016/j.socscimed.2020.113426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.socscimed.2020.113426</ArticleId><ArticleId IdType="pmc">PMC7539940</ArticleId><ArticleId IdType="pubmed">33199035</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung YY, Yao Hui LL, Kraus VB. Colchicine&#x2013;update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45(3):341&#x2013;350. doi: 10.1016/j.semarthrit.2015.06.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2015.06.013</ArticleId><ArticleId IdType="pmc">PMC4656054</ArticleId><ArticleId IdType="pubmed">26228647</ArticleId></ArticleIdList></Reference><Reference><Citation>Imazio M, Brucato A, Cemin R, Ferrua S, Maggiolini S, Beqaraj F, et al. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013;369(16):1522&#x2013;1528. doi: 10.1056/NEJMoa1208536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1208536</ArticleId><ArticleId IdType="pubmed">23992557</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann A, Prosch H, Zehetmayer S, Gysan MR, Bernitzky D, Vonbank K, et al. Impact of persistent D-dimer elevation following recovery from COVID-19. PLoS ONE. 2021;16(10):e0258351. doi: 10.1371/journal.pone.0258351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0258351</ArticleId><ArticleId IdType="pmc">PMC8553152</ArticleId><ArticleId IdType="pubmed">34710097</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok FA, Boon GJAM, Barco S, et al. The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19. Eur Respir J. 2020;56:2001494. 10.1183/13993003.01494-2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7236834</ArticleId><ArticleId IdType="pubmed">32398306</ArticleId></ArticleIdList></Reference><Reference><Citation>Enright PL. The six-minute walk test. Respir Care. 2003. pp. p. 783&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">12890299</ArticleId></ArticleIdList></Reference><Reference><Citation>Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) Qual Life Res. 2011;20(10):1727&#x2013;1736. doi: 10.1007/s11136-011-9903-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-011-9903-x</ArticleId><ArticleId IdType="pmc">PMC3220807</ArticleId><ArticleId IdType="pubmed">21479777</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinson RP. The GAD-7 scale was accurate for diagnosing generalised anxiety disorder. Evid Based Med. 2006;11(6):184. doi: 10.1136/ebm.11.6.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ebm.11.6.184</ArticleId><ArticleId IdType="pubmed">17213178</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606&#x2013;613. doi: 10.1046/j.1525-1497.2001.016009606.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1525-1497.2001.016009606.x</ArticleId><ArticleId IdType="pmc">PMC1495268</ArticleId><ArticleId IdType="pubmed">11556941</ArticleId></ArticleIdList></Reference><Reference><Citation>Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14(5):377&#x2013;381. doi: 10.1249/00005768-198205000-00012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1249/00005768-198205000-00012</ArticleId><ArticleId IdType="pubmed">7154893</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, et al. Development of a fatigue scale. J Psychosom Res. 1993;37(2):147&#x2013;153. doi: 10.1016/0022-3999(93)90081-P.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3999(93)90081-P</ArticleId><ArticleId IdType="pubmed">8463991</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohannon RW, Crouch R. Minimal clinically important difference for change in 6-minute walk test distance of adults with pathology: a systematic review. J Eval Clin Pract. 2017;23(2):377&#x2013;381. doi: 10.1111/jep.12629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jep.12629</ArticleId><ArticleId IdType="pubmed">27592691</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208. doi: 10.1016/j.jbi.2019.103208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2019.103208</ArticleId><ArticleId IdType="pmc">PMC7254481</ArticleId><ArticleId IdType="pubmed">31078660</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Choi T, Al-Aly Z. Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern Med. 2023;183(6):554&#x2013;564. doi: 10.1001/jamainternmed.2023.0743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0743</ArticleId><ArticleId IdType="pmc">PMC10037200</ArticleId><ArticleId IdType="pubmed">36951829</ArticleId></ArticleIdList></Reference><Reference><Citation>Zisis SN, Durieux JC, Mouchati C, Perez JA, McComsey GA. The protective effect of coronavirus disease 2019 (COVID-19) vaccination on postacute sequelae of COVID-19: a multicenter study from a large national health research network. Open Forum Infect Dis. 2022;9(7):ofac228. doi: 10.1093/ofid/ofac228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac228</ArticleId><ArticleId IdType="pmc">PMC9129153</ArticleId><ArticleId IdType="pubmed">35818362</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonilla H, Peluso MJ, Rodgers K, Aberg JA, Patterson TF, Tamburro R, et al. Therapeutic trials for long COVID-19: a call to action from the interventions taskforce of the RECOVER initiative. Front Immunol. 2023;14:1129459. doi: 10.3389/fimmu.2023.1129459.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1129459</ArticleId><ArticleId IdType="pmc">PMC10034329</ArticleId><ArticleId IdType="pubmed">36969241</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>